首页> 美国卫生研究院文献>Journal of the International AIDS Society >Adherence and retention on antiretroviral therapy in a public-private partnership program in Nigeria
【2h】

Adherence and retention on antiretroviral therapy in a public-private partnership program in Nigeria

机译:尼日利亚公私合作项目中抗逆转录病毒疗法的坚持和坚持

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Initiation of HIV-positive patients on antiretroviral therapy (ART) in Nigeria was restricted to secondary and tertiary level hospitals due to weak health systems in primary health centres (PHCs). Shell Petroleum Development Company (SDPC) Nigeria and FHI 360 using a systems strengthening approach, piloted ART enrolment in a PHC in south-eastern Nigeria. This study sought to evaluate patients’ adherence and mortality on ART, and associated risk factors. We reviewed clinic records of adult patients initiating ART between January 2007 and December 2009. Adherence was calculated as the number of days of medication dispensed as a percentage of total number of days evaluated. Outcome measures were probability of being alive and retained in care at 12 and 24 months on ART. Competing risks regression models were used to assess potential predictors associated with mortality. Total of 196 patients (64.8% males) were initiated on ART. Patients’ median age was 35 years (IQR 30–44); median CD4 at initiation was 132 cells/mm3 (IQR 82–212), Patients in WHO stage III and IV constituted 73 (37.6%) and 83 (42.8%) respectively. Majority (108 [55.1%]) of patients had adherence rates >95%. Adherence levels ranged: 70–85%, 50–65% and <50% in 29 (14.8%), 30 (15.3%) and 29 (14.8%) of patients respectively. Nucleoside backbone use were AZT/3TC (69.4%) d4T/3TC (28.6%) and TDF/FTC (2%). At 12 months of follow up, 80.6% (158) were alive and on ART, mortality accounted for 12.8% (25), 11 (5.6%) were LTFU and 2 (1.1%) transferred out. At 24 months on ART survival decreased to 64.3% (126), 20.4% (40) died, 9.2% (18) were LTFU and 12 (6.1%) transferred out. Competing risks regression models revealed that patients’ factors significantly associated with mortality include: bedridden patients (HR=3.6 [95% CI: 1.11–11.45], p=0.03, referent: working), <50% adherence levels (HR=27.7 [95% CI: 8.55–89.47], p<0.0001, referent: >95% adherence level). In conclusion, majority of attrition was due to mortality. Poor adherence was associated with 27 times higher risk of death compared with patients with >95% adherence. Mortality is likely to reduce by establishing a more robust adherence counselling process.
机译:由于初级卫生中心(PHC)的卫生系统薄弱,在尼日利亚,抗病毒治疗(ART)的HIV阳性患者的使用仅限于二级和三级医院。尼日利亚壳牌石油开发公司(SDPC)和FHI 360使用系统加强方法,在尼日利亚东南部的PHC试点了抗逆转录病毒疗法的注册。这项研究旨在评估患者对ART的依从性和死亡率以及相关的危险因素。我们回顾了2007年1月至2009年12月间开始接受抗逆转录病毒治疗的成年患者的临床记录。依从性计算为配药天数占评估天数的百分比。结果指标是接受ART治疗的第12和24个月活着并保留在护理中的可能性。竞争风险回归模型用于评估与死亡率相关的潜在预测因素。总共有196例患者(男性占64.8%)开始接受抗逆转录病毒治疗。患者的中位年龄为35岁(IQR 30-44);起始时CD4的中位数为132个细胞/ mm 3 (IQR 82-212),WHO III和IV期患者分别占73(37.6%)和83(42.8%)。绝大多数(108 [55.1%])患者的依从率> 95%。依从性水平范围为:分别在29(14.8%),30(15.3%)和29(14.8%)的患者中为70-85%,50-65%和<50%。核苷骨架的使用是AZT / 3TC(69.4%)d4T / 3TC(28.6%)和TDF / FTC(2%)。在随访的12个月中,有80.6%(158)活着,接受ART治疗的死亡率占12.8%(25),LTFU占11(5.6%),有2例(1.1%)被转出。接受ART治疗的24个月时,存活率降低至64.3%(126),死亡20.4%(40),LTFU占9.2%(18),另有12(6.1%)转移了出去。竞争风险回归模型显示,与死亡率显着相关的患者因素包括:卧床患者(HR = 3.6 [95%CI:1.11-1.45],p = 0.03,指称:工作),<50%依从性水平(HR = 27.7 [ 95%CI:8.55-89.47],p <0.0001,参考值:> 95%依从性水平)。总而言之,损耗主要归因于死亡率。与依从性> 95%的患者相比,依从性差的患者死亡风险高27倍。通过建立更强大的依从咨询过程,死亡率可能会降低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号